© 2001 The Royal College of Psychiatrists
REVIEW ARTICLE |
New insights into the role of the GABAA—benzodiazepine receptor in psychiatric disorder
Psychopharmacology Unit, University of Bristol
Correspondence: D. J. Nutt, Psychopharmacology Unit, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 ITD, UK. Tel: 0117 925 3066; fax: 0117 927 7057; e-mail: David.J.Nutt{at}bristol.ac.uk
Declaration of interest D.J.N. has received grants from various pharmaceutical companies with an interest in drugs acting at the GABA—benzodiazepine receptor.
Background In the 40 years since the first benzodiazepine was brought into clinical use there has been a substantial growth in understanding the molecular basis of action of these drugs and the role of their receptors in disease states.
Aims To present current knowledge about the role of the GABAA—benzodiazepine receptor in anxiety disorders, new insights into the molecular biology of the receptor complex and neuroimaging studies suggesting involvement of these receptors in disease states.
Method An overview of published literature, including some recent data.
Results The molecular biology of this receptor is detailed. Molecular genetic studies suggesting involvement of the GABAA—benzodiazepine receptor in animal behaviour and learning are outlined; possible parallels with human psychopathology are discussed.
Conclusions Current insights into the role of the GABAA—benzodiazepine receptor in the action of benzodiazepines and as a factor in disease states, in both animals and humans, may lead to new, more sophisticated interventions at this receptor complex and potentially significant therapeutic gains.
This article has been cited by other articles:
 |
|
 |
|
  C. Taylor, J. Nash, A. Rich, A. Lingford-Hughes, D. Nutt, and J. Potokar Assessment of GABAA Benzodiazepine Receptor (GBzR) Sensitivity in Patients with Alcohol Dependence Alcohol Alcohol., November 1, 2008; 43(6): 614 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hasler, A. C. Nugent, P. J. Carlson, R. E. Carson, M. Geraci, and W. C. Drevets Altered Cerebral {gamma}-Aminobutyric Acid Type A-Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography Arch Gen Psychiatry, October 1, 2008; 65(10): 1166 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wilson and D. Nutt Drug treatment of chronic insomnia -- dawn at the end of a long night? J Psychopharmacol, September 1, 2008; 22(7): 703 - 706. [PDF]
|
|
|
|
|
|
D. J. Nutt Alcohol alternatives - a goal for psychopharmacology? J Psychopharmacol, May 1, 2006; 20(3): 318 - 320. [PDF]
|
|
|
|
 |
|
 D. S. Charney Psychobiological Mechanisms of Resilience and Vulnerability: Implications for Successful Adaptation to Extreme Stress Focus, July 1, 2004; 2(3): 368 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Charney Psychobiological Mechanisms of Resilience and Vulnerability: Implications for Successful Adaptation to Extreme Stress Am J Psychiatry, February 1, 2004; 161(2): 195 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Nutt Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors J Psychopharmacol, December 1, 2003; 17(4): 355 - 364. [Abstract] [PDF]
|
|
|
|
 |
|
 P. SAH, E. S. L. FABER, M. LOPEZ DE ARMENTIA, and J. POWER The Amygdaloid Complex: Anatomy and Physiology Physiol Rev, July 1, 2003; 83(3): 803 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. LINGFORD-HUGHES and D. NUTT Neurobiology of addiction and implications for treatment The British Journal of Psychiatry, February 1, 2003; 182(2): 97 - 100. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Paton Benzodiazepines and disinhibition: a review Psychiatr. Bull., December 1, 2002; 26(12): 460 - 462. [Abstract] [Full Text] [PDF]
|
|